Long-acting Triptorelin

PreclinicalSmall molecule

NNanjing University

Long-acting Triptorelin is one of 3 small molecule programs targeting PCOS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PCOSUnknown status

PCOSPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in PCOS

#DrugCompanyPhaseTrials

Precose

Bayer

Preclinical

1 2

GLP-1 Receptor Agonists

JJinling Hospital, China

Preclinical

1 3

Long-acting Triptorelin

NNanjing University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PCOS1 trial

Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI

Unknown status·NNanjing University·N/A·NCT02477566·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Long-acting Triptorelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Long-acting Triptorelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Long-acting Triptorelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNanjing University

Long-acting Triptorelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PCOS1 trial

References

Drug Info

Quick Facts

Related News